OTCMKTS:PXMVF Pixium Vision (PXMVF) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free PXMVF Stock Alerts C$1.50 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's RangeC$1.50▼C$1.5050-Day RangeC$1.50▼C$1.5052-Week RangeC$0.03▼C$0.03VolumeN/AAverage Volume8,800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Pixium Vision alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Pixium Vision Stock (OTCMKTS:PXMVF)Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.Read More PXMVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXMVF Stock News HeadlinesMarch 27, 2024 | macrumors.comWhen Is Apple Vision Pro Coming Out in the UK and Elsewhere?February 2, 2024 | finance.yahoo.comPixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedingsApril 26, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!January 17, 2024 | finance.yahoo.comPostponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024January 17, 2024 | finance.yahoo.comPostponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedingsDecember 18, 2023 | finance.yahoo.comDecision concerning the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings scheduled for January 16, 2024December 4, 2023 | finance.yahoo.comCommercial Court hearing to examine the takeover offer scheduled for December 18, 2023November 20, 2023 | finance.yahoo.comUpdate on the receivership proceedings: submission of a takeover offer to the court-appointed administratorsApril 26, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!November 14, 2023 | finance.yahoo.comPixium Vision announces the 48-Month Trial Results in Severe Atrophic AMDNovember 13, 2023 | finance.yahoo.comPixium Vision announces the conversion of the safeguard proceedings into receivershipNovember 4, 2023 | morningstar.comPixium Vision SA Ordinary SharesOctober 26, 2023 | msn.comPixium Vision SA GAAP EPS of -€0.07, revenue of €0.9MOctober 26, 2023 | finance.yahoo.comPixium Vision announces its financial results for H1 2023 and provides updateOctober 18, 2023 | benzinga.comPixium Vision announces the launch of a process to find buyersOctober 9, 2023 | benzinga.comPixium Vision announces the opening of safeguard proceedingsSeptember 20, 2023 | finance.yahoo.comPixium Vision announces the completion of the reverse stock split of its shares on the basis of 1 new share for 50 existing shares and the start of trading of the shares resulting after the completion of the reverse split as of Sep 21, 2023July 28, 2023 | finance.yahoo.comPixium Vision announces the implementation of a bridge financing with Bpifrance and Sofinnova and a reverse stock split on the basis of 1 new share for 50 existing sharesJuly 11, 2023 | finance.yahoo.comPixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminated ESGO financing facilityJune 15, 2023 | finance.yahoo.comResults of the Annual General Shareholder Meeting as of June 13, 2023June 12, 2023 | finance.yahoo.comPixium Vision announces receipt of € 1.8 million from the French Government as Research Tax CreditJune 9, 2023 | usatoday.comBefore 'car chase,' Duchess Meghan spoke about fighting for equity at Women of Vision galaJune 8, 2023 | finance.yahoo.comPixium Vision announces receipt of € 1.8 million from the French Government as Research Tax CreditMay 24, 2023 | finance.yahoo.comAnnual Meeting of Shareholders June 13, 2023 / Availability of preparatory documentsMay 23, 2023 | wsj.comPixium Vision S.A.May 10, 2023 | finance.yahoo.comPixium Vision convenes its Annual Meeting of Shareholders on June 13, 2023April 25, 2023 | finance.yahoo.comPixium Vision announces the availability of its annual report for the financial year 2022See More Headlines Receive PXMVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pixium Vision and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:PXMVF CUSIPN/A CIKN/A Webwww.pixium-vision.com Phone33 1 76 21 47 68FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Bernard Gilly Ph.D. (Age 67)Executive Chairman Comp: $13kMr. Lloyd Diamond (Age 56)CEO & Director Comp: $436.03kMr. Offer NonhoffChief Financial OfficerDr. Lisa C. Olmos De Koo M.D.MBA, Chief Medical Advisor and Member of the Scientific & Medical CommitteeKey CompetitorsAddLife AB (publ)OTCMKTS:ADDLFAnsellOTCMKTS:ANSLYAnsellOTCMKTS:ANSLFAsahi InteccOTC:AHICFBATM Advanced CommunicationsOTCMKTS:BTAVFView All Competitors PXMVF Stock Analysis - Frequently Asked Questions How have PXMVF shares performed in 2024? Pixium Vision's stock was trading at C$1.50 at the start of the year. Since then, PXMVF stock has increased by 0.0% and is now trading at C$1.50. View the best growth stocks for 2024 here. When did Pixium Vision's stock split? Pixium Vision's stock reverse split on the morning of Thursday, September 21st 2023. The 1-50 reverse split was announced on Thursday, September 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Pixium Vision? Shares of PXMVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PXMVF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pixium Vision SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
